Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 473Brain Neoplasms 306Glioma 257Neoplasms 122Astrocytoma 88Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 70Neuroblastoma 65Central Nervous System Neoplasms 61Melanoma 58Recurrence 46Lung Neoplasms 45Pancreatic Neoplasms 41Oligodendroglioma 37Ovarian Neoplasms 36Colorectal Neoplasms 36Neoplasm Metastasis 33Sarcoma 32Medulloblastoma 28Stomach Neoplasms 27Gliosarcoma 27Lymphoma 25Prostatic Neoplasms 24Head and Neck Neoplasms 24Neurofibromatosis 1 23Rhabdomyosarcoma 21Neurofibroma, Plexiform 19Esophageal Neoplasms 19Diffuse Intrinsic Pontine Glioma 19Cholangiocarcinoma 19

Interventions

TIC10 compound 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Glioblastoma × CNS × Clear all
NCT02038699 2021-04-30

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 1/2 Withdrawn
BreastCNSGastrointestinalThoracic

Advanced Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡